Given the renewed interest in the commercial potential of obesity therapies, Zealand is heralding the potential of its treatments for the overweight.
Having come through a turbulent time in 2022, Zealand Pharma A/S is enthused about this year, especially for its portfolio of assets in the hot area of obesity.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
